{"url":"https://lda.senate.gov/api/v1/filings/322edbbf-e00d-46b3-aab9-22ec802ae768/","filing_uuid":"322edbbf-e00d-46b3-aab9-22ec802ae768","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2025,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/322edbbf-e00d-46b3-aab9-22ec802ae768/print/","filing_document_content_type":"text/html","income":null,"expenses":"260000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Unger Skelton","dt_posted":"2025-07-16T19:37:49-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"c/o 28 Liberty Ship Way, Suite 2815","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Sausalito","registrant_state":"CA","registrant_zip":"94965","registrant":{"id":401103510,"url":"https://lda.senate.gov/api/v1/registrants/401103510/","house_registrant_id":null,"name":"SAREPTA THERAPEUTICS, INC.","description":"Biopharmaceutical company","address_1":"c/o 28 Liberty Ship Way, Suite 2815","address_2":null,"address_3":null,"address_4":null,"city":"Sausalito","state":"CA","state_display":"California","zip":"94965","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE UNGER SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-07-23T16:08:48.090815-04:00"},"client":{"id":199232,"url":"https://lda.senate.gov/api/v1/clients/199232/","client_id":12,"name":"SAREPTA THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-12-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to patient access to treatments Issues related to newborn screening for rare diseases","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139377,"prefix":"mr","prefix_display":"MR.","first_name":"KIP","nickname":null,"middle_name":null,"last_name":"PAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139377,"prefix":"mr","prefix_display":"MR.","first_name":"KIP","nickname":null,"middle_name":null,"last_name":"PAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax issues related to research and development","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139377,"prefix":"mr","prefix_display":"MR.","first_name":"KIP","nickname":null,"middle_name":null,"last_name":"PAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}